The estimated Net Worth of Vimal Mehta is at least $18 million dollars as of 14 June 2024. Mr. Mehta owns over 6,109 units of BioXcel Therapeutics Inc stock worth over $27,320 and over the last 7 years he sold BTAI stock worth over $15,981,498. In addition, he makes $1,968,930 as President, Chief Executive Officer, Co-Founder, Secretary et Director at BioXcel Therapeutics Inc.
Sign up
Mr. Mehta BTAI stock SEC Form 4 insiders trading
Vimal has made over 19 trades of the BioXcel Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 6,109 units of BTAI stock worth $3,360 on 14 June 2024.
The largest trade he's ever made was selling 473,250 units of BioXcel Therapeutics Inc stock on 25 June 2021 worth over $14,590,298. On average, Vimal trades about 29,288 units every 91 days since 2018. As of 14 June 2024 he still owns at least 49,673 units of BioXcel Therapeutics Inc stock.
You can see the complete history of Mr. Mehta stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Vimal Mehta biography
Vimal Mehta Ph.D. serves as President, Chief Executive Officer, Co-Founder, Secretary, Director of the Company. He is a co-founder of BioXcel Corporation and has served as its Chairman of the Board since 2005 and its Chief Executive Officer since September 2014. Dr. Mehta has held various senior scientific and business development positions, including Senior Vice President of Business Development at London-based Inpharmatica Ltd, a global predictive informatics company, from 2002 to 2006 and Senior Vice President, Business Development for Jubilant Life Sciences, an integrated global pharmaceutical and life sciences company, from 2006 to 2007. Previously, Dr. Mehta served as Business Development Manager at CuraGen Corporation, a biotechnology company, from 1996 to 2002. He held multiple positions in the Department of Radiology at the University of Texas, Southwestern Medical Center from 1989 to 1996, including Postdoctoral Fellow, Instructor and Assistant Professor. Dr. Mehta holds a Ph.D. in Chemistry from the University of Delhi, India and completed a Post-Doctoral Fellowship in Chemistry at the University of Montpellier, France. During the length of his career, Dr. Mehta has garnered a deep understanding of the biopharma and healthcare ecosystem and has been actively involved in diverse global value generating initiatives encompassing corporate strategy and planning, global business development, and corporate fundraising. He has helped to shape the company's strategic and business trajectory which the Board believes qualifies him to serve as a director of our company.
What is the salary of Vimal Mehta?
As the President, Chief Executive Officer, Co-Founder, Secretary et Director of BioXcel Therapeutics Inc, the total compensation of Vimal Mehta at BioXcel Therapeutics Inc is $1,968,930. There are no executives at BioXcel Therapeutics Inc getting paid more.
How old is Vimal Mehta?
Vimal Mehta is 59, he's been the President, Chief Executive Officer, Co-Founder, Secretary et Director of BioXcel Therapeutics Inc since 2017. There are 6 older and 8 younger executives at BioXcel Therapeutics Inc. The oldest executive at BioXcel Therapeutics Inc is Dr. Frank D. Yocca Ph.D., 65, who is the Sr. VP & Chief Scientific Officer.
What's Vimal Mehta's mailing address?
Vimal's mailing address filed with the SEC is C/O BIOXCEL THERAPEUTICS, INC., 555 LONG WHARF DRIVE, 12TH FLOOR, NEW HAVEN, CT, 06511.
Insiders trading at BioXcel Therapeutics Inc
Over the last 7 years, insiders at BioXcel Therapeutics Inc have traded over $63,244,788 worth of BioXcel Therapeutics Inc stock and bought 45,656 units worth $321,105 . The most active insiders traders include Vimal Bio Xcel Holdings, In..., Vimal Mehta et Krishnan Nandabalan. On average, BioXcel Therapeutics Inc executives and independent directors trade stock every 30 days with the average trade being worth of $29,814. The most recent stock trade was executed by Matthew T. Wiley on 15 June 2024, trading 750 units of BTAI stock currently worth $413.
What does BioXcel Therapeutics Inc do?
bioxcel therapeutics, inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. the company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. the company's two most advanced clinical development programs are bxcl501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and bxcl701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.
What does BioXcel Therapeutics Inc's logo look like?
Complete history of Mr. Mehta stock trades at BioXcel Therapeutics Inc
BioXcel Therapeutics Inc executives and stock owners
BioXcel Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Vimal Mehta,
President, Chief Executive Officer, Co-Founder, Secretary, Director -
Dr. Vimal D. Mehta Ph.D.,
Founder, CEO, Pres, & Director -
Frank Yocca,
Chief Scientific Officer -
Vincent O'Neill,
Chief Medical Officer -
Richard Steinhart,
Chief Financial Officer -
Peter Mueller,
Independent Chairman of the Board -
Sandeep Laumas,
Independent Director -
Dr. Krishnan Nandabalan,
Chief Digital Officer ?& Director -
Michal Votruba,
Independent Director -
John Graziano,
IR Contact Officer -
Reina Benabou,
Senior Vice President, Chief Development Officer -
Will Kane,
Executive Vice President, Chief Commercial Officer -
Krishnan Nandabalan,
Co-Founder, Director, Chief Digital Officer -
Matthew Wiley,
Sr. VP & Chief Commercial Officer -
Dr. Iris Francesconi Ph.D.,
Sr. VP of Marketing, Market Research & Commercial Assessments -
Dr. Frank D. Yocca Ph.D.,
Sr. VP & Chief Scientific Officer -
Richard I. Steinhart MBA,
Sr. VP & CFO -
Dr. Reina Benabou M.D., Ph.D.,
Sr. VP & Chief Devel. Officer -
William P. Kane Jr.,
Exec. VP & Chief Commercial Officer -
Dr. David C. Hanley,
Head of Global Pharmaceutical Devel. and Operations & VP -
Dr. Cedric Burg,
VP and Head of Global Clinical Operations & Project Management -
Javier Rodriguez,
Sr. VP, Chief Legal Officer & Corp. Sec. -
Mary Coleman,
VP of Investment Relations -
Dr. Vincent J. O'Neill M.D., B.Sc., M.R.C.P.,
Sr. VP & Chief Medical Officer -
Llc Bio Xcel,
10% owner -
Holdings, Inc. Bio Xcel,
10% owner -
Matthew T. Wiley,
Chief Commercial Officer -
Michael Patrick Miller,
Director -
June Bray,
Director -
Vimal Bio Xcel Holdings, In...,
CEO and President